Evidence map›Paper›PMID 31976350›Full record

ArticleJournal of biological methods2020

Comparing NGS and NanoString platforms in peripheral blood mononuclear cell transcriptome profiling for advanced heart failure biomarker development.

Galyna Bondar, Wenjie Xu, David Elashoff, Xinmin Li, Emmanuelle Faure-Kumar, Tra-Mi Bao, Tristan Grogan, Jim Moose, Mario C Deng

Open access · diamondAbstract read
In one paragraph

Article in Journal of biological methods, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Developing a Predictive Model for Metastatic Potential in Pancreatic Neuroendocrine Tumor.The Journal of clinical endocrinology and metabolism · 2024
    Article
  5. Article
  6. Challenges and opportunities in processing NanoString nCounter data.Computational and structural biotechnology journal · 2024
    Review
  7. Article
  8. Article
  9. Article
  10. Lung-resident CD69The Journal of allergy and clinical immunology · 2023
    Article
  11. Article
  12. Development and Validation of a Parsimonious Tuberculosis Gene Signature Using the digital NanoString nCounter Platform.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Multi-dimensional COVID-19 short- and long-term outcome prediction algorithm.Expert review of precision medicine and drug development · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Galyna BondarDavid Geffen School of Medicine, University of California Los Angeles Medical Center, Los Angeles, CA 90095, USA.
Wenjie XuNanostring Technologies, Seattle, WA 98109, USA.
David ElashoffDavid Geffen School of Medicine, University of California Los Angeles Medical Center, Los Angeles, CA 90095, USA.
Xinmin LiDavid Geffen School of Medicine, University of California Los Angeles Medical Center, Los Angeles, CA 90095, USA.
Emmanuelle Faure-KumarDavid Geffen School of Medicine, University of California Los Angeles Medical Center, Los Angeles, CA 90095, USA.
Tra-Mi BaoDavid Geffen School of Medicine, University of California Los Angeles Medical Center, Los Angeles, CA 90095, USA.
Tristan GroganDavid Geffen School of Medicine, University of California Los Angeles Medical Center, Los Angeles, CA 90095, USA.
Jim MooseLeukoLifeDx, Point Pleasant, NJ 08742, USA.
Mario C DengDavid Geffen School of Medicine, University of California Los Angeles Medical Center, Los Angeles, CA 90095, USA.
University of California, Los Angeles · USLos Angeles Medical Center · USNanostring Technologies (United States) · US

Funding

Pilot and Feasibility ProgramP30DK041301 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ROZENGURT, JUAN ENRIQUE · 1990 to 2019
$18.0M
Multidimensional Molecular Biomarkers of MultiOrgan Dysfunction after MCS TherapyR21HL120040 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DENG, MARIO C. · 2014 to 2015
$421k
NHLBI NIH HHS R21 HL120040NIDDK NIH HHS P30 DK041301
6 · The paper itself

Abstract

In preparation to create a clinical assay that predicts 1-year survival status of advanced heart failure (AdHF) patients before surgical/interventional therapies and to select the appropriate clinical assay platform for the future assay, we compared the properties of next generation sequencing (NGS) used in the gene discovery phase to the NanoString platform used in the clinical assay development phase. In 25 AdHF patients in a tertiary academic medical center from 2015 to 2016, PBMC samples were collected and aliquoted for NGS RNA whole transcriptome sequencing and compared to 770 genes represented on NanoString's PanCancer IO 360 Gene Expression research panel. Prior to statistical analysis, NanoString and NGS expression values were log transformed. We computed Pearson correlation coefficients for each sample, comparing gene expression values between NanoString and NGS across the set of matched genes and for each of the matched genes across the set of samples. Genes were grouped by average NGS expression, and the NanoString-NGS correlation for each group was computed. Out of 770 genes from the NanoString panel, 734 overlapped between both platforms and showed high intrasample correlation. Within an individual sample, there was an expression-level dependent correlation between both platforms. The low-

Indexed as

advanced heart failurebiomarkerNanoStringnext generation sequencingprediction test

Identifiers

PMID31976350
PMCPMC6974694
OpenAlexW2996770311

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.